HER1/EGFR Targeting: Refining the Strategy

HER1/EGFR Targeting: Refining the Strategy Roman Perez-Soler Oncologist 2004; 9: 58-67 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Differentiate between ligand-dependent and ligand-independent human epidermal growth factor receptor tyrosine kinase activation and initiation of signaling. Describe the site of action of tyrosine kinase inhibitors and explain how this might impact their therapeutic profiles. Discuss the influence of all aspects of clinical trial design on measurable outcomes, including dosing regimen, protocol, and patient selection. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 30, 2004 Most Recent Review: Jan. 30, 2004* Most Recent Update: Jan. 30, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.